Since most cell models are imported from Europe and the United States, the basic biomedical research and drug research that our country has invested a lot of resources are actually making bride clothes for others. Most of the research focuses on diseases of Westerners rather than diseases of Chinese people.
Chinas biomedical industry is weak in original innovation ability, and there are only a handful of drugs with real original innovation and international influence. It is not only difficult to meet the national health needs, but also easy to be in a passive situation in the international industrial chain.
The United States, the United Kingdom, the Netherlands, Sweden and South Korea are all vigorously developing this technology in order to compete for strategic control over the international biomedical field.
When the pain of IC industry lack of core touched the Chinese people, a chip competition in biomedical industry has quietly begun.
The lack of independent innovation has always been a pain in the development of Chinas bio pharmaceutical industry. One of the pain points is the cell model known as the original chip of the biomedical industry.
Cell model is the core element and strategic source resource of basic biomedical research and drug research and development, which determines the original innovation ability of biomedical industry. Cell models in China have been constrained by human beings and become a neck-tie link restricting Chinas biomedical industry.
Watching Newsweek reporters recently learned from the Hefei Institute of Material Sciences, Chinese Academy of Sciences that the vast majority of cell models depend on imports from Europe and the United States. The basic biomedical research and drug research that China has invested a lot of resources in is actually making bridal clothes for others. Most of the research focuses on diseases of Westerners. Not Chinese disease. At the same time, Chinas biomedical industry is weak in original innovation ability. There are only a handful of truly original innovations and internationally influential drugs, which are not only difficult to meet national health needs, but also easy to be in a passive situation in the international industrial chain.
Now, with the east wind of precision medicine, the opportunity to upgrade and replace cells model emerges. Can our country get rid of the pain of lack of core in biopharmaceutical industry?
Shooting someone elses target with someone elses gun.
In recent years, Liu Qingsong Pharmaceutical Research Team, Hefei Institute of Material Sciences, Chinese Academy of Sciences, has made breakthroughs in targeting anti-cancer pharmacology and clinical pharmacogenomics. Within a few years, the worlds largest high-throughput cell screening library based on cancer kinase target has been established, which covers the current situation. Most of the known kinase and kinase mutations associated with tumorigenesis and development are known. This means that relying on the cell bank, the effectiveness and toxicity of anticancer drugs can be detected more accurately and rapidly in drug development. Its completion fills in the blank of this kind of detection system in the field of new drug creation in China, and provides strong support for the development of new anti-cancer drugs.
However, as the teams research and development in the field of biomedicine goes deeper, researchers feel more and more embarrassed that the original innovation ability is restricted by others.
Liu Qingsong, the team leader and researcher, told Looking News Weekly that in the current research and intervention on cancer, academia and industry use immortalized cell models derived from the West, which reflect the genetic background of Western patients, while many diseases, due to different races and environments. Its phenotype and mechanism are different. Therefore, our research and development in this model is like shooting someone elses target with someone elses gun. Liu Qingsong said.
The source dependence of the cell model leads to the government investing a lot of resources in the basic research of health industry, to a certain extent, it is making marriages for others. For example, the incidence of gastric cancer and hepatocellular carcinoma in the United States is low, so there are few studies, while in China, the incidence of gastric cancer and hepatocellular carcinoma is high, but there are few corresponding innovative drug research and development.
The source dependence of cell model also makes the development of bio pharmaceutical industry in China be controlled by others. For example, DSMZ, a European cell operation company, has an exclusive cell model, but it has imposed some cell embargoes on China in the name of protecting intellectual property rights. According to the regulatory requirements prevailing all over the world, the relevant enterprises in China must prove that they have used the cell resources from legal sources in product development, which is for our enterprises. The development of related diseases has set up barriers to industry development.
Seize the opportunity to change the road and overtake the car.
According to the reporter of Look News Weekly, cell model is the chip of biomedical industry developed in Europe and America in the 1960s. Currently, cancer cell models have been used for decades. These immortalized cell lines have been cultured for thousands of generations and adapted to a completely different culture dish environment from their original environment. Cell genome formation and biological behavior have changed, and there are a lot of cross-contamination. The problem.
In addition, the biological behavior of these limited cell lines represents only a part of the pathological condition of individual patients used to establish cell lines, but ignores the pathological heterogeneity of different patients even in the same disease. This leads to a low conversion rate of basic research and clinical application of drug research results.
This situation is obviously unable to meet the needs of precision medical care. Therefore, in the era when personalized therapy becomes the mainstream of precise medical treatment, more and more countries begin to abandon immortalized cell models and develop primary cell models that can better reflect the pathological characteristics of cancer patients. For example, in early 2016, the National Cancer Institute announced that it would stop using the NCI-60 immortal cell system, which has been used for decades in basic cancer research and drug development, and recommended replacing the original cancer cell lines with patientsprimary cancer cells.
In Liu Qingsongs view, This is a huge transformation and industrial upgrading in the development process of biomedical industry, which is equivalent to the problem of cell model, and the world is on the same starting line.
Liu Qingsong explained that primary cancer cells are the basic strategic resources for basic pathological research and the best personalized detection model for drug development. The high incidence of cancer in China does not coincide with that in other countries. For the same kind of cancer, the molecular typing in China does not coincide with that in other countries. Therefore, to study cancer in China, we must rely on the primary cells of Chinese people for basic pathological research and industrial development, so as to make the drugs we developed targeted and adapt to the pathogenesis of Chinese people.
Obviously, in this round of competition, who has mastered the source strategic resources and key technologies of renewable primary cancer cells, who has controlled the industry from the strategic source. According to Liu Qingsong, in recent years, the United States, Britain, the Netherlands, Sweden, South Korea and other countries are vigorously developing this technology to compete for strategic control of the international biomedical field.
Although the use of cancer patientsprimary cells for research and industrial development has gradually become a consensus in the industry, this idea has not been widely applied due to the small amount of cancer cell tissues obtained from cancer patients, the very low survival rate of primary cells cultured in vitro, and the limited expansion algebra.
This makes the development of rapid primary cell amplification technology that does not change the pathological characteristics become the key technology to achieve the use of primary cancer cells.
It is understood that in recent years, Liu Qingsong and his team in the field of precise medical treatment of cancer clinical precise drug use technology developed in many provinces in China to promote the application, contacted thousands of patients with fresh tissue samples, for the new cancer primary cell in vitro amplification technology research provides a wealth of clinical resources support. On this basis, the team has developed a variety of reprogramming in vitro amplification techniques for cancer primary cells, which can achieve large-scale expansion of primary cells within 1 to 4 weeks. Moreover, gene detection showed that the primary cells involved in more than 10 Chinese multiple cancers, such as leukemia, breast cancer and lung cancer, basically retained the patients original genome pathological information, and within six generations, the drug sensitivity remained basically the same.
Liu Qingsong said that although the team has achieved a technological breakthrough in rapid expansion of cancer primary cells, the resources of cell models are limited after all. In view of the national demand for cancer biomedicine development, it is still urgent to establish a Chinese-based biobank for renewable cancer primary cells.
According to the reporters understanding, the Biobank of Primary Cells for Renewable Cancer takes the rapid expansion technology of primary cells as the core, collects the resources of cancer tissues, transforms them into primary cells for renewable cancer through a series of technological reforms, and then integrates the resources of cells for basic scientific research and industrial output, and has out through in and out. Similar banking operation mode can provide the source of technological resources for cancer research and diagnosis and treatment in China.
Liu Qingsong explains that the reason why it is called cell bank is because it wants 3 characteristics:
First, there are gains and gains, not just preservation.
The two is large volume, which fully reflects the diversity of pathology.
Thirdly, we should increase the quantity of biological samples by technological transformation.
According to our reporters interview, there are currently no less than 300 biological sample banks in the world, mainly distributed in North America, Europe and Asia, but these biological sample banks are mainly dead banks which can not be accessed. Their sample types include blood products, bone marrow, DNA/RNA and so on. The living cell biological bank owners are currently under construction. In the United States, Britain and Holland.
Researchers interviewed believed that cancer was an important obstacle to the implementation of Chinas strategy for health. Currently, basic research and industrial development of cancer accounted for the majority of biomedicine. The Renewable Cancer Primary Cell Biobank is a basic resource bank for cancer research in China, which is helpful for our country to get rid of the situation that cancer biology research relies heavily on Europe and the United States for decades, and further strengthen the discourse power of basic resources in medical research in our country, so as to give full play to our countrys overtaking in the field of basic medical research. Important role.
Liu Qingsong said that relying on this basic resource pool, large data on drug susceptibility can be integrated in the future, and a guideline for cancer pathological molecular typing and clinical drug use in China can be established, which will provide precise, reliable, sustained and stable testing resources for the new drug manufacturing industry in China, and support the creation and new refinement of new drugs for multiple cancers in China. Quasi detection means research and development.
Liu Qingsong has received many help information from cancer patients. He said that what impressed him most was a 10 year old girl a few years ago. The girl had acute myeloid leukemia, a FLT3 mutation that had not yet been treated. The girls father toss and turn to find Liu Qingsong, hoping that the drugs they develop can save their children. However, at that time, Liu Qingsongs research was only in the basic research stage, which made the girls father very disappointed. The girls father told Liu Qingsong that her daughter was very strong and kept urging him to go online to find out if he had succeeded in the latest drug research and development. The daughter also said that she was sure to be well. Liu Qingsong said, Later, I consulted the literature and did some experiments to find a possible targeted medicine for the little girl. Unfortunately, the little girl died after the telephone call. Speaking of this, Liu Qingsongs eyes are moist. Many cancer patients are racing against life, and Liu Qingsong, eager to contribute to the health of the Chinese people, are racing against time. Can China seize the tremendous opportunity of cell model upgrading and substitution to get rid of the pain of core deficiency in cancer biomedicine? Source: lookout editor: Yang Yi _NBJ10647
Liu Qingsong has received many help information from cancer patients. He said that what impressed him most was a 10 year old girl a few years ago. The girl had acute myeloid leukemia, a FLT3 mutation that had not yet been treated. The girls father toss and turn to find Liu Qingsong, hoping that the drugs they develop can save their children. However, at that time, Liu Qingsongs research was only in the basic research stage, which made the girls father very disappointed. The girls father told Liu Qingsong that her daughter was very strong and kept urging him to go online to find out if he had succeeded in the latest drug research and development. The daughter also said that she was sure to be well.
Liu Qingsong said, Later, I consulted the literature and did some experiments to find a possible targeted medicine for the little girl. Unfortunately, the little girl died after the telephone call. Speaking of this, Liu Qingsongs eyes are moist.
Many cancer patients are racing against life, and Liu Qingsong, eager to contribute to the health of the Chinese people, are racing against time. Can China seize the tremendous opportunity of cell model upgrading and substitution to get rid of the pain of core deficiency in cancer biomedicine?